Baseline clinical characteristic of 47 t(15;17) APL patients
| Group/case no. . | PML-RARα . | FLT3 . | FLT3-ITD . | Chromosome . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Isoform . | Sex . | Age, y . | WBC, ×109/L . | Blast, % . | D835 . | ITD . | Level, % . | ||
| NC | |||||||||
| 5 | S | F | 43 | 1.9 | 88 | - | - | 46,XX,t(15;17)(q22;q21) | |
| 48 | S | M | 45 | 1.3 | 76 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 23 | L | F | 38 | 0.4 | 84 | - | - | ND, RT-PCR(+) | |
| 28 | L | F | 36 | 9.9 | 87 | - | - | ND, RT-PCR(+) | |
| 35 | L | F | 60 | 1.0 | 94 | - | - | 46,XX,t(15;17)(q22;q21) | |
| 40 | L | M | 32 | 0.9 | 75 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 12 | L | M | 54 | 1.3 | 97 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 55 | L | M | 36 | 2.0 | 76 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 56 | L | M | 17 | 1.9 | 85 | - | - | ND, RT-PCR(+) | |
| 24 | V | M | 32 | 0.9 | 77 | - | - | 46,XY,t(15;17)(q22;q12) | |
| 46 | V | M | 33 | 2.8 | 62 | - | - | ND, RT-PCR(+) | |
| 33 | S | M | 42 | 31.4 | 88 | +H | - | 46,XY,t(15;17)(q22;q21) | |
| 1 | L | F | 68 | 1.3 | 96 | +Y | - | 46,XX,t(15;17)(q22;q21) | |
| 9 | L | F | 30 | 1.4 | 87 | +Y | - | 46,XX,t(15;17)(q22;q21) | |
| 11 | L | M | 30 | 4.3 | 78 | +D | - | ND, RT-PCR(+) | |
| 53 | L | M | 36 | 36.2 | 96 | +E | - | 46,XY,t(15;17)(q22;q21) | |
| 61 | L | M | 32 | 0.3 | 93 | +E | - | ND, RT-PCR(+) | |
| 7 | S | F | 31 | 120.0 | 95 | - | + | 42 | 46,XX,t(15;17)(q22;q12) |
| 8 | S | M | 49 | 4.5 | 96 | - | + | 37 | 46,XY,t(15;17)(q22;q21) |
| 14 | S | M | 9 | 28.0 | 80 | - | + | 40 | 46,XY,t(15;17)(q22;q21) |
| 17 | S | F | 47 | 51.1 | 98 | - | + | 24 | 46,XX,t(15;17)(q22;q21) |
| 29 | S | M | 75 | 1.5 | 88 | - | + | 35 | ND, RT-PCR(+) |
| 63 | S | F | 57 | 9.7 | 96 | - | + | 42 | 46,XX,t(15;17)(q22;q21) |
| 64 | S | M | 28 | 24.8 | 90 | - | + | 57 | 46,XY,t(15;17)(q22;q21) [25/26] |
| 46,XY[1/26] | |||||||||
| 6 | L | F | 37 | 29.5 | 93 | - | + | 32 | ND, RT-PCR(+) |
| 42 | L | F | 24 | 1.2 | 87 | - | + | 4 | 46,XX,t(15;17)(q22;q21) |
| 51 | L | M | 51 | 45.4 | 78 | - | + | 47 | 46,XY,t(15;17)(q21;q12) |
| 62 | L | F | 46 | 45.0 | 89 | - | + | 42 | 46,XX,t(15;17) (q22;q21) |
| +8 | |||||||||
| 65 | S | F | 58 | 1.5 | 87 | - | - | 46,XX,RT-PCR(+) | |
| 38 | L | F | 22 | 7.0 | 78 | - | - | 47,XX,+8,t(15;17)(q22;q12) | |
| 2 | S | M | 42 | 2.4 | 79 | - | - | 47,XY,+8,t(15;17)(q22;q21) | |
| 50 | S | F | 58 | 19.8 | 84 | - | - | 47,XX,+8,t(15;17)(q22;q21) | |
| 60 | L | M | 22 | 9.9 | 90 | +H | - | 46,XY,t(15;17)(q22;q21) [16/21] | |
| 47XY,+8,t(15;17) (q22;q21) [4/21] | |||||||||
| 46,XY [1/21] | |||||||||
| 3 | V | M | 33 | 3.2 | 67 | - | - | 47,XY,+8,t(15;17)(p22;q12) | |
| 39 | L | M | 38 | 1.0 | 51 | - | - | 47,XY,+8,t(15;17)(q22;q21) | |
| 18 | L | M | 23 | 18.1 | 94 | - | - | ND, RT-PCR(+) | |
| Other | |||||||||
| 66 | S | F | 41 | 15.6 | 89 | +Y | - | 46,XX,t(15;17)(q22;q11.2) | |
| 20 | L | F | 51 | 77.9 | 88 | - | - | 46,XX,t(15;17)(q22;q21) | |
| 13 | L | F | 7 | 1.6 | 99 | +Y | - | ND, RT-PCR(+) | |
| 4 | S | M | 68 | 0.7 | 91 | +E | - | 46,XY,t(15;17)(q22;q21) | |
| 37 | S | F | 26 | 2.0 | 75 | +Y | - | 46,XX,t(15;17)(q22;q12) | |
| 57 | L | F | 30 | 1.4 | 87 | +Y | - | 46,XX,t(15;17)(q22;q21) | |
| 19 | L | M | 51 | 1.1 | 73 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 21 | L | M | 45 | 4.7 | 87 | - | - | ND, RT-PCR(+) | |
| 43 | L | M | 7 | 8.6 | 75 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 52 | L | M | 54 | 8.6 | 82 | - | - | 46,XY,t(15;17)(q21;q12) [19/20] | |
| 47,XY, +21, t(15;17)(q21;q12) [1/20] | |||||||||
| 58 | L | F | 27 | 6.9 | 90 | - | - | 46,XX,t(15;17)(q22;q21)ider(17) (q10)t(15;17) [23/26] | |
| 46,XX [3/26] | |||||||||
| Group/case no. . | PML-RARα . | FLT3 . | FLT3-ITD . | Chromosome . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Isoform . | Sex . | Age, y . | WBC, ×109/L . | Blast, % . | D835 . | ITD . | Level, % . | ||
| NC | |||||||||
| 5 | S | F | 43 | 1.9 | 88 | - | - | 46,XX,t(15;17)(q22;q21) | |
| 48 | S | M | 45 | 1.3 | 76 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 23 | L | F | 38 | 0.4 | 84 | - | - | ND, RT-PCR(+) | |
| 28 | L | F | 36 | 9.9 | 87 | - | - | ND, RT-PCR(+) | |
| 35 | L | F | 60 | 1.0 | 94 | - | - | 46,XX,t(15;17)(q22;q21) | |
| 40 | L | M | 32 | 0.9 | 75 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 12 | L | M | 54 | 1.3 | 97 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 55 | L | M | 36 | 2.0 | 76 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 56 | L | M | 17 | 1.9 | 85 | - | - | ND, RT-PCR(+) | |
| 24 | V | M | 32 | 0.9 | 77 | - | - | 46,XY,t(15;17)(q22;q12) | |
| 46 | V | M | 33 | 2.8 | 62 | - | - | ND, RT-PCR(+) | |
| 33 | S | M | 42 | 31.4 | 88 | +H | - | 46,XY,t(15;17)(q22;q21) | |
| 1 | L | F | 68 | 1.3 | 96 | +Y | - | 46,XX,t(15;17)(q22;q21) | |
| 9 | L | F | 30 | 1.4 | 87 | +Y | - | 46,XX,t(15;17)(q22;q21) | |
| 11 | L | M | 30 | 4.3 | 78 | +D | - | ND, RT-PCR(+) | |
| 53 | L | M | 36 | 36.2 | 96 | +E | - | 46,XY,t(15;17)(q22;q21) | |
| 61 | L | M | 32 | 0.3 | 93 | +E | - | ND, RT-PCR(+) | |
| 7 | S | F | 31 | 120.0 | 95 | - | + | 42 | 46,XX,t(15;17)(q22;q12) |
| 8 | S | M | 49 | 4.5 | 96 | - | + | 37 | 46,XY,t(15;17)(q22;q21) |
| 14 | S | M | 9 | 28.0 | 80 | - | + | 40 | 46,XY,t(15;17)(q22;q21) |
| 17 | S | F | 47 | 51.1 | 98 | - | + | 24 | 46,XX,t(15;17)(q22;q21) |
| 29 | S | M | 75 | 1.5 | 88 | - | + | 35 | ND, RT-PCR(+) |
| 63 | S | F | 57 | 9.7 | 96 | - | + | 42 | 46,XX,t(15;17)(q22;q21) |
| 64 | S | M | 28 | 24.8 | 90 | - | + | 57 | 46,XY,t(15;17)(q22;q21) [25/26] |
| 46,XY[1/26] | |||||||||
| 6 | L | F | 37 | 29.5 | 93 | - | + | 32 | ND, RT-PCR(+) |
| 42 | L | F | 24 | 1.2 | 87 | - | + | 4 | 46,XX,t(15;17)(q22;q21) |
| 51 | L | M | 51 | 45.4 | 78 | - | + | 47 | 46,XY,t(15;17)(q21;q12) |
| 62 | L | F | 46 | 45.0 | 89 | - | + | 42 | 46,XX,t(15;17) (q22;q21) |
| +8 | |||||||||
| 65 | S | F | 58 | 1.5 | 87 | - | - | 46,XX,RT-PCR(+) | |
| 38 | L | F | 22 | 7.0 | 78 | - | - | 47,XX,+8,t(15;17)(q22;q12) | |
| 2 | S | M | 42 | 2.4 | 79 | - | - | 47,XY,+8,t(15;17)(q22;q21) | |
| 50 | S | F | 58 | 19.8 | 84 | - | - | 47,XX,+8,t(15;17)(q22;q21) | |
| 60 | L | M | 22 | 9.9 | 90 | +H | - | 46,XY,t(15;17)(q22;q21) [16/21] | |
| 47XY,+8,t(15;17) (q22;q21) [4/21] | |||||||||
| 46,XY [1/21] | |||||||||
| 3 | V | M | 33 | 3.2 | 67 | - | - | 47,XY,+8,t(15;17)(p22;q12) | |
| 39 | L | M | 38 | 1.0 | 51 | - | - | 47,XY,+8,t(15;17)(q22;q21) | |
| 18 | L | M | 23 | 18.1 | 94 | - | - | ND, RT-PCR(+) | |
| Other | |||||||||
| 66 | S | F | 41 | 15.6 | 89 | +Y | - | 46,XX,t(15;17)(q22;q11.2) | |
| 20 | L | F | 51 | 77.9 | 88 | - | - | 46,XX,t(15;17)(q22;q21) | |
| 13 | L | F | 7 | 1.6 | 99 | +Y | - | ND, RT-PCR(+) | |
| 4 | S | M | 68 | 0.7 | 91 | +E | - | 46,XY,t(15;17)(q22;q21) | |
| 37 | S | F | 26 | 2.0 | 75 | +Y | - | 46,XX,t(15;17)(q22;q12) | |
| 57 | L | F | 30 | 1.4 | 87 | +Y | - | 46,XX,t(15;17)(q22;q21) | |
| 19 | L | M | 51 | 1.1 | 73 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 21 | L | M | 45 | 4.7 | 87 | - | - | ND, RT-PCR(+) | |
| 43 | L | M | 7 | 8.6 | 75 | - | - | 46,XY,t(15;17)(q22;q21) | |
| 52 | L | M | 54 | 8.6 | 82 | - | - | 46,XY,t(15;17)(q21;q12) [19/20] | |
| 47,XY, +21, t(15;17)(q21;q12) [1/20] | |||||||||
| 58 | L | F | 27 | 6.9 | 90 | - | - | 46,XX,t(15;17)(q22;q21)ider(17) (q10)t(15;17) [23/26] | |
| 46,XX [3/26] | |||||||||
Chromosomal translocation of t(15;17) was determined by karyotype studies and/or RT-PCR analysis specific for PML-RARα fusion products. Three types of PML-RARα (long, short, and variant) are shown as L, S, and V, respectively. The recorded number of white blood cells (WBCs) and bone marrow blast percentages were obtained at diagnosis. Mutations of FLT3 were either tyrosine kinase domain (TKD) at codon 835 or internal tandem repeat (ITD). The APL samples are divided into 3 groups based on SNP-chip analysis: normal-copy-number (NC), trisomy 8 including duplication of the MYC gene region (+8), and other abnormalities (other).